Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review

Oostenbrugge, Tim J. van; Fütterer, Jurgen J.; Mulders, Peter F.A.

doi:10.3233/kca-180028

Cited by 90 publications

(96 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our preliminary report, we applied 1 H NMR and gas chromatography mass spectrometry (GCMS) based metabolomics analyses to urine and serum specimens to differentiate between benign and malignant renal masses in a small patient cohort (53 samples). In that study, we found that glycolytic and TCA cycle metabolites in blood and urine significantly separated benign lesions from ccRCC [11]. The present study is aimed at validating this previously identified urinary metabolic signature within a larger, external RCC cohort (Vanderbilt Cohort) in addition to exploring the metabolic differences between histologic subtypes of RCC.…”

Section: Introductionmentioning

confidence: 80%

“…Secondly, benign lesions were compared with samples of ccRCC histology, a comparison most closely related to the groups compared in our previous study in which 92.5% of the RCC samples analyzed were ccRCC [11]. Distinct group separations were confirmed (Figure 2) and the metrics were similar to previously reported data; whereby, benign versus pT1 (R2Y = 0.42; Q2 = 0.27; Figure 2a) and benign versus pT2 showed the best group separation without overlap between the groups (R2Y = 0.96; Q2 = 0.82; Figure 2b).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

et al. 2019

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a heterogeneous malignancy which often develops and progresses asymptomatically. Benign oncocytomas are morphologically similar to malignant chromophobe RCC and distinguishing between these two forms on cross-sectional imaging remains a challenge. Therefore, RCC-specific biomarkers are urgently required for accurate and non-invasive, pre-surgical diagnosis of benign lesions. We have previously shown that dysregulation in glycolytic and tricarboxylic acid cycle intermediates can distinguish benign lesions from RCC in a stage-specific manner. In this study, preoperative fasting urine samples from patients with renal masses were assessed by ¹H nuclear magnetic resonance (NMR). Significant alterations in levels of tricarboxylic acid cycle intermediates, carnitines and its derivatives were detected in RCC relative to benign masses and in oncocytomas vs. chromophobe RCC. Orthogonal Partial Least Square Discriminant Analysis plots confirmed stage discrimination between benign vs. pT1 (R2 = 0.42, Q2 = 0.27) and benign vs. pT3 (R2 = 0.48, Q2 = 0.32) and showed separation for oncocytomas vs. chromophobe RCC (R2 = 0.81, Q2 = 0.57) and oncocytomas vs. clear cell RCC (R2 = 0.32, Q2 = 0.20). This study validates our previously described metabolic profile distinguishing benign tumors from RCC and presents a novel metabolic signature for oncocytomas which may be exploited for diagnosis before cross-sectional imaging.

show abstract

Section: Introductionmentioning

confidence: 80%

Section: Resultsmentioning

confidence: 99%

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most frequent presenting symptoms were abdominal lump or mass (28, 93.33%) followed by abdominal pain (26,86.67%), weight loss (25, 83.33%), anorexia (20, 66.67%), fever (19, 63.33%), jaundice (18, 60.00%), hematuria (12, 40.00%) and others ( Table 2). Many clinical presentations occurred in combination like abdominal mass with abdominal pain.…”

Section: Resultsmentioning

confidence: 99%

“…25 CT scan has the advantage over ultrasound in accurately delineating a renal mass and differentiating pseudomasses and anatomical variants. 26 Following the treatment of renal masses, CT scan is the method of choice for post nephrectomy renal fossa surveillance. 27 CT is better than ultrasound in staging of Wilm's tumour.…”

Section: Discussionmentioning

confidence: 99%

Role of computed tomography scan in diagnosis of retroperitoneal masses

Patel

2020

Int Surg J

View full text Add to dashboard Cite

Background: In the vast and ever-expanding field of surgery there are only few subjects which have provoked controversy; curiosity related to correct management of patients suffering from various condition of the abdomen. This becomes very true when the patient has a retroperitoneal mass clinically. The problem of retroperitoneal mass was intriguing, fascinating and certainly most perplexing. The present study was planned with the objective to study the various clinical presentations of retroperitoneal mass, and their radiological findings, and co-relation between these various findings.Methods: This was a prospective, cross-sectional study. The study included 30 patients clinically diagnosed having retroperitoneal mass, attending the department of general surgery.Results: The most common affected age group was of 40-50 years (9, 30.00%). The most frequent presenting symptoms were abdominal lump (28, 93.33%). Pallor was the commonest clinical sign (20, 66.67%). Retroperitoneal lymph node masses were the commonest (12, 40.00%) malignant lesions. Retroperitoneal lymphadenopathy was the most common lesion.Conclusions: The retroperitoneum has long been an area poorly visualised by conventional radiographic techniques and in this respect, computed tomography scan has great advantages over other modalities. Hence the modern surgeon should no longer be considered a ‘shadow-gazer' but an anatomist in-vivo.

show abstract

“…Magnetic resonance imaging (MRI) is not recommended for routine clinical practice but may provide additional information on venous involvement by tumour thrombus. However, for tumours sized ≤ 20 mm in diameter, gadoliniumenhanced sequences with fat saturation have been shown to be more sensitive than contrast-enhanced CT [7].…”

Section: Diagnosismentioning

confidence: 99%

SEOM clinical guideline for treatment of kidney cancer (2019)

et al. 2020

View full text Add to dashboard Cite

In this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent advances in molecular biology have allowed the subclassification of renal tumours into different histologic variants and may help to identify future prognostic and predictive factors. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. No adjuvant therapy has demonstrated a clear benefit in overall survival. Considering the whole population of patients with advanced disease, the combination of axitinib with either pembrolizumab or avelumab increase response rate and progression-free survival, compared to sunitinib, but a longer overall survival has only been demonstrated so far with the pembrolizumab combo. For patients with IMDC intermediate and poor prognosis, nephrectomy should not be considered mandatory. In this subpopulation, the combination of ipilimumab and nivolumab has also demonstrated a superior response rate and overall survival vs. sunitinib. In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC.

show abstract

Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review

Cited by 90 publications

References 84 publications

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

Role of computed tomography scan in diagnosis of retroperitoneal masses

SEOM clinical guideline for treatment of kidney cancer (2019)

Contact Info

Product

Resources

About